RU2426130C2 - Экспресс-тест для диагностирования болезни альцгеймера - Google Patents

Экспресс-тест для диагностирования болезни альцгеймера Download PDF

Info

Publication number: RU2426130C2
Authority: RU; Russia
Prior art keywords: antibody; disease; lymphocytes; stimulation; cells
Prior art date: 2003-10-22

Application number

RU2006112203/10A

Other languages

English (en)

Russian (ru)

Other versions

RU2006112203A (ru

Inventor

Томас АРЕНДТ (DE)

Томас АРЕНДТ

Дженс СТИЛЕР (DE)

Дженс СТИЛЕР

Original Assignee

Лейпцигский Университет

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-22

Filing date

2004-09-29

Publication date

2011-08-10

2004-09-29 Application filed by Лейпцигский Университет filed Critical Лейпцигский Университет

2007-11-27 Publication of RU2006112203A publication Critical patent/RU2006112203A/ru

2011-08-10 Application granted granted Critical

2011-08-10 Publication of RU2426130C2 publication Critical patent/RU2426130C2/ru

Links

208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 40
238000002405 diagnostic procedure Methods 0.000 title abstract description 9
230000000638 stimulation Effects 0.000 claims abstract description 55
102100025137 Early activation antigen CD69 Human genes 0.000 claims abstract description 25
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims abstract description 25
210000004698 lymphocyte Anatomy 0.000 claims abstract description 18
230000002073 mitogenetic effect Effects 0.000 claims abstract description 17
239000000126 substance Substances 0.000 claims abstract description 3
210000004027 cell Anatomy 0.000 claims description 45
238000000034 method Methods 0.000 claims description 27
239000006249 magnetic particle Substances 0.000 claims description 18
210000004369 blood Anatomy 0.000 claims description 13
239000008280 blood Substances 0.000 claims description 13
239000000523 sample Substances 0.000 claims description 13
102000004169 proteins and genes Human genes 0.000 claims description 11
108090000623 proteins and genes Proteins 0.000 claims description 11
239000013068 control sample Substances 0.000 claims description 9
239000003226 mitogen Substances 0.000 claims description 8
230000002297 mitogenic effect Effects 0.000 claims description 6
239000003146 anticoagulant agent Substances 0.000 claims description 5
229940127219 anticoagulant drug Drugs 0.000 claims description 5
239000000243 solution Substances 0.000 claims description 5
238000012360 testing method Methods 0.000 claims description 5
238000011088 calibration curve Methods 0.000 claims description 4
210000000601 blood cell Anatomy 0.000 claims description 3
230000004962 physiological condition Effects 0.000 claims description 3
238000000926 separation method Methods 0.000 claims description 3
241000219506 Phytolacca Species 0.000 claims description 2
239000008004 cell lysis buffer Substances 0.000 claims description 2
239000003153 chemical reaction reagent Substances 0.000 claims description 2
230000009089 cytolysis Effects 0.000 claims 2
230000006641 stabilisation Effects 0.000 claims 1
238000011105 stabilization Methods 0.000 claims 1
239000003550 marker Substances 0.000 abstract description 10
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
239000000090 biomarker Substances 0.000 description 11
206010012289 Dementia Diseases 0.000 description 6
108010047620 Phytohemagglutinins Proteins 0.000 description 6
230000001885 phytohemagglutinin Effects 0.000 description 6
208000020016 psychiatric disease Diseases 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
150000001875 compounds Chemical class 0.000 description 5
238000002955 isolation Methods 0.000 description 5
102000039446 nucleic acids Human genes 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
210000004927 skin cell Anatomy 0.000 description 5
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 4
230000004913 activation Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000001228 trophic effect Effects 0.000 description 3
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000000975 dye Substances 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
238000005567 liquid scintillation counting Methods 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
230000008569 process Effects 0.000 description 2
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
-1 CD45RO Proteins 0.000 description 1
102100025222 CD63 antigen Human genes 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000009830 intercalation Methods 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
230000005291 magnetic effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Cell Biology (AREA)
General Health & Medical Sciences (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Tropical Medicine & Parasitology (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Hospice & Palliative Care (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Psychiatry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)

RU2006112203/10A 2003-10-22 2004-09-29 Экспресс-тест для диагностирования болезни альцгеймера RU2426130C2 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10349162A DE10349162A1 (de)	2003-10-22	2003-10-22	Schnelltest zur Diagnose der Alzheimerschen Erkrankung
DE10349162.7		2003-10-22

Publications (2)

Publication Number	Publication Date
RU2006112203A RU2006112203A (ru)	2007-11-27
RU2426130C2 true RU2426130C2 (ru)	2011-08-10

Family

ID=34529710

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2006112203/10A RU2426130C2 (ru)	2003-10-22	2004-09-29	Экспресс-тест для диагностирования болезни альцгеймера

Country Status (15)

Country	Link
US (2)	US20070218497A1 (sr)
EP (1)	EP1685408A1 (sr)
JP (1)	JP2007509331A (sr)
KR (1)	KR101138343B1 (sr)
CN (1)	CN1871519A (sr)
AU (1)	AU2004290789B2 (sr)
BR (1)	BRPI0415212A (sr)
CA (1)	CA2540841A1 (sr)
DE (1)	DE10349162A1 (sr)
IL (1)	IL175004A0 (sr)
NO (1)	NO335704B1 (sr)
RS (2)	RS52875B (sr)
RU (1)	RU2426130C2 (sr)
WO (1)	WO2005050219A1 (sr)
ZA (1)	ZA200603178B (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1876449A1 (en) *	2006-07-07	2008-01-09	Universität Leipzig	Cell cycle-based blood test to diagnose Alzheimer's disease
WO2010084312A1 (en) *	2009-01-20	2010-07-29	Cambridge Enterprise Limited	Methods for predicting autoimmune disease risk
GB201212084D0 (en) *	2012-07-06	2012-08-22	Randox Lab Ltd	Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment
WO2014205406A1 (en) *	2013-06-20	2014-12-24	Amarantus Bioscience Holdings, Inc.	Methods, systems, and composition related to neural disorders
CN106885909B (zh) *	2017-01-19	2018-11-20	上海市东方医院	一种用于早期诊断阿尔茨海默病的试剂盒
WO2018165161A1 (en)	2017-03-06	2018-09-13	Novartis Ag	Methods and compositions for determining the potency of a therapeutic cellular composition
US20220260595A1 (en) *	2019-07-10	2022-08-18	Todos Medical Ltd.	A biomarker for alzheimer's disease using blood samples from clinically diagnosed alzheimer's disease subjects
CN117210549B (zh) *	2023-08-29	2025-03-07	遵义市第一人民医院(遵义医学院第三附属医院)	检测人atp5d、cd69和cxcr4基因的物质及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19936035C2 (de) *	1999-07-30	2002-11-21	Univ Leipzig	Lymphozytenproliferationstestkit
US20020081635A1 (en) *	2000-05-11	2002-06-27	Thomas Terry E.	Novel antibody compositions for preparing enriched T cell preparations

2003
- 2003-10-22 DE DE10349162A patent/DE10349162A1/de not_active Ceased
2004
- 2004-09-29 RS RS20060255A patent/RS52875B/sr unknown
- 2004-09-29 JP JP2006535981A patent/JP2007509331A/ja active Pending
- 2004-09-29 AU AU2004290789A patent/AU2004290789B2/en not_active Ceased
- 2004-09-29 RS YUP-2006/0255A patent/RS20060255A/sr unknown
- 2004-09-29 BR BRPI0415212-3A patent/BRPI0415212A/pt not_active Application Discontinuation
- 2004-09-29 RU RU2006112203/10A patent/RU2426130C2/ru not_active IP Right Cessation
- 2004-09-29 KR KR1020067009613A patent/KR101138343B1/ko not_active Expired - Fee Related
- 2004-09-29 CN CNA2004800310040A patent/CN1871519A/zh active Pending
- 2004-09-29 EP EP04765688A patent/EP1685408A1/de not_active Ceased
- 2004-09-29 US US10/576,142 patent/US20070218497A1/en not_active Abandoned
- 2004-09-29 CA CA002540841A patent/CA2540841A1/en not_active Abandoned
- 2004-09-29 WO PCT/EP2004/010889 patent/WO2005050219A1/de not_active Ceased
2006
- 2006-04-11 IL IL175004A patent/IL175004A0/en active IP Right Grant
- 2006-04-20 ZA ZA200603178A patent/ZA200603178B/xx unknown
- 2006-04-20 NO NO20061758A patent/NO335704B1/no not_active IP Right Cessation
2014
- 2014-07-09 US US14/326,520 patent/US20150079609A1/en not_active Abandoned

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STIELER J.T. et al., «Impairment of mitogenic activation of peripheral blood lymphocytes in Alzheimer's disease», Neuroreport, 2001, v. 12, n. 18, p.3969-3972. ПОНОМАРЕВА Н.В. и др., Нервно-иммунные взаимодействия при нормальном старении и болезни. Вестник РАМН, 1995, №12, с.27-32. АНДРОСОВА Л.В. и др. Связь функциональной активности лимфоцитов крови больных деменциями альцгеймерского типа с их реакцией на терапию. Журнал Неврологии и Психиатрии, 1998, №5, с.43-46. *

Also Published As

Publication number	Publication date
RU2006112203A (ru)	2007-11-27
AU2004290789A1 (en)	2005-06-02
DE10349162A1 (de)	2005-06-02
CA2540841A1 (en)	2005-06-02
NO20061758L (no)	2006-07-06
BRPI0415212A (pt)	2006-12-05
KR20060100423A (ko)	2006-09-20
RS52875B (sr)	2013-12-31
JP2007509331A (ja)	2007-04-12
ZA200603178B (en)	2007-07-25
US20150079609A1 (en)	2015-03-19
KR101138343B1 (ko)	2012-04-26
CN1871519A (zh)	2006-11-29
EP1685408A1 (de)	2006-08-02
NO335704B1 (no)	2015-01-26
IL175004A0 (en)	2006-08-20
AU2004290789B2 (en)	2010-01-21
RS20060255A (sr)	2008-09-29
WO2005050219A1 (de)	2005-06-02
US20070218497A1 (en)	2007-09-20

Legal Events

Date	Code	Title	Description
2009-06-20	FZ9A	Application not withdrawn (correction of the notice of withdrawal)	Effective date: 20090420
2010-04-20	FA92	Acknowledgement of application withdrawn (lack of supplementary materials submitted)	Effective date: 20100303
2010-05-20	FZ9A	Application not withdrawn (correction of the notice of withdrawal)	Effective date: 20100402
2021-09-08	MM4A	The patent is invalid due to non-payment of fees	Effective date: 20200930

Publication	Publication Date	Title
US6780606B1 (en)	2004-08-24	Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
US20150079609A1 (en)	2015-03-19	Quick test for the diagnosis of alzheimer's disease
AU2788400A (en)	2000-09-21	Method for diagnosing and distinguishing stroke
CN107167610B (zh)	2019-12-06	自闭症生物标志物及其检测试剂盒
CN108474798A (zh)	2018-08-31	表征细胞特异性微囊泡的方法
US20110177531A1 (en)	2011-07-21	Cell-Based Complement Activation Product Algorithm for Diagnosing Systemic Lupus Erythematosus
US6461825B1 (en)	2002-10-08	Immunometric assay kit and method applicable to whole cells
US20250264479A1 (en)	2025-08-21	Functional assay for quickly determining immune status
RU2523418C1 (ru)	2014-07-20	Способ оценки нарушений клеточного иммунитета при воздействии фенола
US20250012804A1 (en)	2025-01-09	Use of microvesicles for benign colorectal polyps and colorectal cancer screening
AU2011215826B2 (en)	2016-09-29	Compositions and methods for predicting cardiovascular events
RU2697395C1 (ru)	2019-08-14	Способ прогнозирования идиопатического бесплодия мужчин
US20220170908A1 (en)	2022-06-02	Compositions and methods for characterizing and treating alzheimers disease
RU2258934C9 (ru)	2007-11-10	Способ прогнозирования течения нервно-психических заболеваний
Sow et al.	2017	Comparison of para-selles bailenger/Kop-color fumouze, para-selles-iodésine/Kop-color II fumouze diagnostic kits with conventional microscopic methods in identifying intestinal parasitic diseases in Senegal
RU2803276C1 (ru)	2023-09-12	Способ прогнозирования когнитивных нарушений у пациентов с сотрясением головного мозга и ушибом головного мозга лёгкой степени тяжести
Shokouhi et al.	2018	Diagnostic value of the leukocyte esterase test for early detection of pleocytosis in cerebrospinal fluid of patients with suspected acute bacterial meningitis
MXPA06004451A (en)	2007-04-20	Quick test for the diagnosis of alzheimer'disease
Godbole et al.	2019	Role of C-reactive protein (CRP) in determining neonatal infections
RU2214599C2 (ru)	2003-10-20	Способ выявления лиц, относящихся к группе риска по развитию аллергических заболеваний
US20040157277A1 (en)	2004-08-12	Methods for predicting and/or diagnosing the risk of gastric cancer
KR20220018149A (ko)	2022-02-15	인라인 마이크로 튜브세트를 이용한 잠복결핵 감염 검사방법
likMaker oi VIDAS et al.	0	Trends in rapid testing
UA21744U (en)	2007-03-15	Method for diagnosing predisposition to tumors of endometrium